The Pennsylvania Dutchman Vol. 8, No. 3

● The Dutch Touch in Iron ● The Pennsylvania Dutch Village ● Five June Days ● On an Amish Farm ● Traveling Pennsylvanians ● The Trail of the Stone Arched Bridges in Berks County ● Displaced Dutchmen Crave Shoo-flies ● Florence Starr Taylor ● Pennsylvania Dutch Pioneers ● Zinzendorf and Moravian Research ● Sheep in Dutchlandhttps://digitalcommons.ursinus.edu/dutchmanmag/1010/thumbnail.jp

Polymer Composite and Nanocomposite Dielectric Materials for Pulse Power Energy Storage

This review summarizes the current state of polymer composites used as dielectric materials for energy storage. The particular focus is on materials: polymers serving as the matrix, inorganic fillers used to increase the effective dielectric constant, and various recent investigations of functionalization of metal oxide fillers to improve compatibility with polymers. We review the recent literature focused on the dielectric characterization of composites, specifically the measurement of dielectric permittivity and breakdown field strength. Special attention is given to the analysis of the energy density of polymer composite materials and how the functionalization of the inorganic filler affects the energy density of polymer composite dielectric materials

Spitzer Warm Mission Archive Science Opportunities

The rich data archive from the Spitzer cryogenic mission will be comprised of approximately 25 TB of data. A five-year warm mission would add an additional 15–20 TB. All of these data will be processed and archived to form homogeneous, reliable database to support research for decades after the end of the Spitzer mission. The SSC proposes a robust archival research program during the warm mission phase. A sampling of possible archival programs are described

Defining the critical hurdles in cancer immunotherapy

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer